Why the study?
Does noninvasive ultrasonic biopsy predict the progression of arteriosclerosis and risk of cardiovascular events in asymptomatic, hyperlipidemic, and diabetic subjects?
Does noninvasive ultrasonic biopsy predict the progression of arteriosclerosis and risk of cardiovascular events in asymptomatic, hyperlipidemic, and diabetic subjects?
Noninvasive ultrasonic biopsy of the carotid and femoral bifurcation is a useful tool for tracking arteriosclerosis progression and identifying patients at risk for cardiovascular events.
Answers are grounded in this paper and cite their sources.
Ultrasonic biopsy may stratify risk in high-risk asymptomatic patients; leaves open whether findings should guide therapy pending prospective validation.
Noninvasive ultrasonic biopsy (UB) is a method of detecting early arteriosclerotic changes by high-resolution ultrasound scanning of the carotid and femoral bifurcation. Six UB classes (scoring 0 to 10) have been identified in 2000 asymptomatic subjects and 600 vascular patients followed up for four years. The incidence of silent coronary ischemia (tested by effort test) and the occurrence of symptomatic events in four years are increased in advanced classes and with increasing UB score. The rate of progression (ROP) in four years to the next UB class has been defined in normal subjects (1.4% in class I, 3.1% in II, 10.7% in III, 17.9% in IV, and 79.2% in class V). In a group of 305 asymptomatic hyperlipidemic subjects and in a group of 269 diabetics the ROP (in four years) was significantly higher. Therefore ultrasonic biopsy is useful to identify subjects at risk of coronary ischemia and cardiovascular events and to follow up noninvasively the progression of arteriosclerosis.
No takes yet. Share an insight, caveat, or question.
Belcaro et al. (1993) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: